Gynecological cancer｜司会・講師のご紹介

Gynecological cancer｜Disccusion

解説【LBA28】ENGOT-en11/GOG-3053/KEYNOTE-B21: A Phase 3 Study of Pembrolizumab or Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Patients With Newly Diagnosed, High-Risk Endometrial Cancer

西川 忠曉　Nishikawa Tadaaki
（東京慈恵会医科大学 産婦人科学講座）

解説【LBA29】Final overall survival (OS) in patients (pts) with newly diagnosed advanced ovarian cancer (aOC) treated with niraparib (nir) first-line (1L) maintenance: results from PRIMA/ENGOT-OV26/GOG-3012

西川 忠曉　Nishikawa Tadaaki
（東京慈恵会医科大学 産婦人科学講座）

解説【LBA30】ATHENA-COMBO, a phase 3, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC)
【LBA32】A randomized, Phase 2, dose optimization of gotistobart, a pH-sensitive anti-CTLA-4, in combination with standard dose pembrolizumab in platinum-resistant recurrent ovarian cancer: safety, efficacy and dose optimization (PRESERVE-004/GOG-3081)

西川 忠曉　Nishikawa Tadaaki
（東京慈恵会医科大学 産婦人科学講座）